http://schca-ir.schmc.ac.kr/handle/2022.oak/147 Fri, 13 Nov 2026 07:24:59 GMT 2026-11-13T07:24:59Z http://schca-ir.schmc.ac.kr/handle/2022.oak/5051 Title: Publisher Correction: Evaluation of familial phenotype deviation to measure the impact of de novo mutations in autism All Author(s): Soo-Whee Kim; Hyeji Lee; Da Yea Song; Gang-Hee Lee; Jae Hyun Han; Jee Won Lee; Hee Jung Byun; Ji Hyun Son; Ye Rim Kim; Yoojeong Lee; Eunjoon Kim; Donna M Werling; So Hyun Kim; Stephan J Sanders; Hee Jeong Yoo; Joon-Yong An Tue, 31 Dec 2024 15:00:00 GMT http://schca-ir.schmc.ac.kr/handle/2022.oak/5051 2024-12-31T15:00:00Z http://schca-ir.schmc.ac.kr/handle/2022.oak/5048 Title: Korean Medication Algorithm for Depressive Disorder 2025, Fifth Revision: An Executive Summary All Author(s): Nak-Young Kim; Jeong Seok Seo; Won-Myong Bahk; Won-Seok Choi; Sheng-Min Wang; Young Sup Woo; Won Kim; Sung-Yong Park; Jung Goo Lee; Chan-Mo Yang; Sang-Yeol Lee; Hyung Mo Sung; Young-Eun Jung; Moon-Doo Kim; Jong-Hyun Jeong; Duk-In Jon; Bo-Hyun Yoon; Se-Hoon Shim; Kyung Joon Min Abstract: Objective: Since its development in 2002 by the Korean College of Neuropsychopharmacology and the Korean Society for Affective Disorders, the Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) has undergone five revisions. Methods: To improve survey efficiency, reflect general clinical practice, and facilitate comparisons with previous KMAP-DD revisions, the overall structure of the questionnaire was retained. The six sections of the questionnaire were as follows: 1) pharmacological treatment strategies for major depressive disorder with and without psychotic features; 2) pharmacological treatment strategies for persistent depressive disorder and other depressive disorder subtypes; 3) consensus on treatment-resistant depression; 4) selection of an antidepressant in consideration of safety, adverse effects, and comorbid physical conditions; 5) treatment strategies for special populations (children/adolescents, elderly, and women); and 6) non-pharmacological biological therapies. First-, second-, and third-line treatment recommendations were statistically derived. Results: Compared to KMAP-DD 2021, only minor changes were noted, due to the limited introduction of new medications or treatment modalities. Nonetheless, notable shifts included an increased preference for atypical antipsychotics (AAPs), and higher preference of combination strategies involving AAPs and mood stabilizers, indicating a more proactive and intensive treatment trend in Korea. Conclusion: KMAP-DD is expected to serve as a valuable clinical resource by providing expert consensus-based recommendations on specific treatment strategies and pharmacological options for major depressive disorders, thereby supporting the integration of real-world clinical practice with evidence-based medicine. Tue, 31 Dec 2024 15:00:00 GMT http://schca-ir.schmc.ac.kr/handle/2022.oak/5048 2024-12-31T15:00:00Z http://schca-ir.schmc.ac.kr/handle/2022.oak/5050 Title: Evaluation of familial phenotype deviation to measure the impact of de novo mutations in autism All Author(s): Soo-Whee Kim; Hyeji Lee; Da Yea Song; Gang-Hee Lee; Jae Hyun Han; Jee Won Lee; Hee Jung Byun; Ji Hyun Son; Ye Rim Kim; Yoojeong Lee; Eunjoon Kim; Donna M Werling; So Hyun Kim; Stephan J Sanders; Hee Jeong Yoo; Joon-Yong An Abstract: Background: The phenotypic outcomes of de novo variants (DNVs) in autism spectrum disorder (ASD) exhibit wide variability. To date, no study has comprehensively estimated DNV effects accounting for familial phenotypic background. Methods: To evaluate DNV effects in a family-relative context, we defined within-family standardized deviations (WFSD) by subtracting phenotype scores of unaffected family members and standardizing the result. We applied this approach to 78,685 individuals from 21,735 families from ASD cohorts of diverse ancestries. We compared the distribution, associations with disruptive DNVs, and gene discovery results between WFSD and raw phenotype scores. We further performed outlier analysis based on WFSDs per gene to detect genes with high variability between families. Results: We observed that ASD probands with disruptive DNVs exhibited greater behavioral symptoms and lower adaptive functioning relative to their within-family unaffected members. Compared to raw phenotype scores, WFSD provided clearer associations with DNVs and enabled greater yield in DNV-enriched gene discovery, including 18 novel ASD-associated genes. Outlier analysis identified 11 genes with high intrafamilial variability in phenotypic effects, influenced by mutation sites within functional domains or exons. Conclusions: Familial DNV analysis provides accurate effect estimates, a reliable basis for predicting clinical outcomes, and precise support while minimizing confounding from family background. This approach improves the identification of ASD-associated genes with true phenotypic effects by reducing variability, as well as genes with genuine phenotypic heterogeneity across families driven by mutation site. These findings enhance our understanding of ASD phenotype variability and inform potential targets for intervention. Tue, 31 Dec 2024 15:00:00 GMT http://schca-ir.schmc.ac.kr/handle/2022.oak/5050 2024-12-31T15:00:00Z http://schca-ir.schmc.ac.kr/handle/2022.oak/5027 Title: Hospital-Based Psychosocial Case Management and Suicide Prevention in South Korea: A Randomized Clinical Trial All Author(s): Sang Min Lee; Kyoung-Hoon Kim; Kyu-Man Han; Min-Hyuk Kim; Min-Kyoung Kim; Kwang-Yeon Choi; A-La Park; Myungjae Baik; Ah Rah Lee; Peter Jongho Na; Hyeon-Ah Lee; Hwa-Young Lee; Jong-Woo Paik Abstract: Importance: South Korea maintains the highest suicide rate in the Organization for Economic Cooperation and Development, with major depressive disorder (MDD) being the leading diagnosis among suicide deaths. Evidence from large-scale randomized clinical trials (RCTs) is limited, particularly for diagnosis-specific, long-term programs in outpatient settings. Objective: To evaluate the effectiveness of a structured, hospital-based case management program in reducing suicidal ideation and associated clinical outcomes among patients with MDD. Design, setting, and participants: This RCT was conducted at 6 general hospitals in South Korea from January 18, 2021, to July 31, 2024. Participants included outpatients 18 years or older with MDD who had current suicidal ideation or a suicide attempt within the past 2 months. All efficacy analyses were performed according to the intention-to-treat principle. Intervention: Participants were randomized 1:1 to receive either 6 months of structured assertive case management (ACM) as an adjunct to standard treatment (n = 158) or usual psychiatric care alone (control [n = 156]). Main outcomes and measures: The primary outcome was the change from baseline to 6 months in the overall severity of suicidal thoughts and behaviors (STBs), as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS). Secondary outcomes included changes in depression, suicidal intent and ideation, anxiety, loneliness, impulsivity, quality of life, and service utilization. Results: Of 314 participants enrolled (mean [SD] age, 32.3 [13.1] years; 207 [65.9%] female), 158 were randomized to the ACM group and 156 to the control group; 245 (132 in the ACM and 113 in the control groups) completed the 6-month follow-up. The ACM group showed a significantly greater mean (SD) reduction in C-SSRS total score than the control group (-9.22 [0.49] vs -7.23 [0.50]; adjusted mean difference, -1.99 [95% CI, -3.37 to -0.61]; P = .005). Greater mean improvements were also observed in the ACM group for depressive symptoms (Hamilton Depression Rating Scale mean [SD] change, -9.19 [0.70] vs -6.23 [0.69]; P = .003), suicidal ideation (Beck Scale for Suicidal Ideation mean [SD] change, -7.96 [0.62] vs -5.58 [0.75]; P = .01), and anxiety (Generalized Anxiety Disorder-7 mean [SD] change, -3.90 [0.44] vs -1.85 [0.48]; P = .002). No significant between-group differences were observed in suicide attempts, and 1 suicide death occurred in the control group. Conclusions and relevance: In this RCT of outpatients with MDD and high suicide risk, ACM significantly reduced C-SSRS total scores and psychological distress compared with usual care. These findings provide a critical, high-level evidence base for the national implementation of standardized, hospital-centered psychosocial interventions as a scalable public health strategy for suicide prevention. Trial registration: Clinical Research Information Service Identifier: KCT0008123. Wed, 31 Dec 2025 15:00:00 GMT http://schca-ir.schmc.ac.kr/handle/2022.oak/5027 2025-12-31T15:00:00Z